Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE M 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE M 300.
ISOVUE-250 vs ISOVUE-M 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Iopamidol is a nonionic, low-osmolality iodinated contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing the visibility of vascular structures and organs during imaging procedures. It acts by absorbing X-rays due to the high atomic number of iodine.
Intravenous administration of 50-150 mL (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 mL (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
1.0-2.0 mL/kg intravenous bolus for CT imaging up to a total of 150 mL per procedure; intra-arterial dosing varies by procedure, typical adult dose 30-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Terminal elimination half-life: approximately 2 hours (range 1.5–2.5 hours). Normal renal function; prolonged in renal impairment.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Primarily renal excretion via glomerular filtration; unchanged drug: >95% excreted in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Contrast Media
Contrast Media